Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in AtriCure, Inc. or AdaptHealth Corp. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how AtriCure, Inc. and AdaptHealth Corp. compare based on key financial metrics to determine which better meets your investment needs.
About AtriCure, Inc. and AdaptHealth Corp.
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula’s to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
AdaptHealth Corp., together with its subsidiaries, distributes home medical equipment (HME), medical supplies, and home and related services in the United States. It operates through Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home segments. The company offers sleep therapy equipment, supplies, and related services, such as continuous positive airway pressure and BiLevel services to individuals suffering from obstructive sleep apnea; oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services; and medical devices, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; and other HME devices and supplies. It also provides PAP machines, wheelchairs, hospital beds, oxygen concentrators, ventilators, insulin pumps, diabetes management and wound care supplies, orthopedic bracing, breast pumps and supplies, walkers, commodes, enteral supplies, and incontinence supplies. The company services beneficiaries of Medicare, Medicaid, and commercial insurance payors. AdaptHealth Corp. was founded in 2012 and is headquartered in Conshohocken, Pennsylvania.
Latest Health Care Equipment & Supplies and AtriCure, Inc., AdaptHealth Corp. Stock News
As of September 2, 2026, AtriCure, Inc. had a $2.7 billion market capitalization, compared to the Health Care Equipment & Supplies median of $416.1 million. AtriCure, Inc.’s stock is up 31.6% in 2026, up 5.7% in the previous five trading days and up 44.92% in the past year.
Currently, AtriCure, Inc.’s price-earnings ratio is 249.2. AtriCure, Inc.’s trailing 12-month revenue is $569.6 million with a 1.9% net profit margin. Year-over-year quarterly sales growth most recently was 12.9%. Analysts expect adjusted earnings to reach $0.284 per share for the current fiscal year. AtriCure, Inc. does not currently pay a dividend.
As of September 2, 2026, AdaptHealth Corp. had a $805.8 million market cap, putting it in the 42nd percentile of all stocks. AdaptHealth Corp.’s stock is down 38.9% in 2026, up 4.9% in the previous five trading days and down 33.99% in the past year.
Currently, AdaptHealth Corp. does not have a price-earnings ratio. AdaptHealth Corp.’s trailing 12-month revenue is $3.4 billion with a -6.8% net profit margin. Year-over-year quarterly sales growth most recently was 12.7%. Analysts expect adjusted earnings to reach $-0.454 per share for the current fiscal year. AdaptHealth Corp. does not currently pay a dividend.
How We Compare AtriCure, Inc. and AdaptHealth Corp. Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at AtriCure, Inc. and AdaptHealth Corp.’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions
AtriCure, Inc. and AdaptHealth Corp. Stock Value Grades
| Company | Ticker | Value |
| AtriCure, Inc. | ATRC | F |
| AdaptHealth Corp. | AHCO | A |
Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.
Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.
AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.
Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.
AtriCure, Inc. has a Value Score of 7, which is Ultra Expensive.
AdaptHealth Corp. has a Value Score of 83, which is Deep Value.
The Value Stock Winner: AdaptHealth Corp.
As you can clearly see from the Value Grade breakdown above, AdaptHealth Corp. is considered to have better value than AtriCure, Inc.. For investors who focus solely on a company’s valuation, AdaptHealth Corp. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.
AtriCure, Inc. and AdaptHealth Corp.’s Quality Grades
| Company | Ticker | Quality |
| AtriCure, Inc. | ATRC | B |
| AdaptHealth Corp. | AHCO | C |
Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.
The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.
The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.
Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.
AtriCure, Inc. has a Quality Score of 77, which is Strong.
AdaptHealth Corp. has a Quality Score of 46, which is Average.
The Quality Grade Winner: AtriCure, Inc.
As you can clearly see from the Quality Grade breakdown above, AtriCure, Inc. has a better overall quality grade than AdaptHealth Corp.. For investors who are looking for companies with higher quality than others in the same industry, AtriCure, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.
AtriCure, Inc. and AdaptHealth Corp.’s Momentum Grades
| Company | Ticker | Momentum |
| AtriCure, Inc. | ATRC | A |
| AdaptHealth Corp. | AHCO | F |
Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.
Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.
AtriCure, Inc. has a Momentum Score of 96, which is Very Strong.
AdaptHealth Corp. has a Momentum Score of 14, which is Very Weak.
The Momentum Grade Winner: AtriCure, Inc.
As you can clearly see from the Momentum Grade breakdown above, AtriCure, Inc. is considered to have stronger momentum compared to AdaptHealth Corp.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, AtriCure, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.
Don’t Forget Your Free Special Report on How A+ Grades Can Help You Make Investment Decisions
Other AtriCure, Inc. and AdaptHealth Corp. Grades
In addition to Value, Momentum and Quality, A+ Investor also provides grades for Growth and Estimate Revisions.
Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).
Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.
These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether AtriCure, Inc. and AdaptHealth Corp. pass any of our 60+ stock screens that have outperformed the market since their creation.
So, Which Is the Better Investment, AtriCure, Inc. or AdaptHealth Corp. Stock?
Overall, AtriCure, Inc. stock has a Value Score of 7, Momentum Score of 96 and Quality Score of 77.
AdaptHealth Corp. stock has a Value Score of 83, Momentum Score of 14 and Quality Score of 46.
Comparing AtriCure, Inc. and AdaptHealth Corp.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.
Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.
A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.
AAII Disclaimer
We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.
Included With AAII Platinum
at only 23.3%
Since Inception. Data as of 12/31/2024.
769.3% Stock Superstars Portfolio Total Return Since Inception
U.S. Index ETF (IYY)
SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.
FREE REPORT
BECOME A MEMBER FOR ONLY $2
Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.